New combo therapy targets hard-to-treat solid tumors
Disease control
Not yet recruiting
This early-stage trial tests a new drug, JCXH-211, injected directly into tumors along with an anti-PD-1 antibody given through a vein. The goal is to see if this combination is safe and tolerable for people with advanced solid tumors who have not responded to standard treatments…
Phase: PHASE1, PHASE2 • Sponsor: Immorna Biotherapeutics, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC